rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    XNCR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Xencor director Richard Ranieri sells $3.19 million in shares
      Nov 16Investing.comXNCR
      Xencor director Richard Ranieri sells $3.19M in stock
      Nov 13Investing.comXNCR
      Early Arthritis Data Could Be A Big Test For Xencor Stock (XNCR)

      Xencor reported third quarter 2026 net income of US$39.44 million and positive earnings per share, while year to date results still show a net loss of US$111.21 million, underscoring the financial weight of its ongoing research programs. Initial Phase 1b data for subcutaneous plamotamab in rheumatoid arthritis, released at ACR 2026, showed deep B-cell depletion linked with reductions in disease activity. This highlights how Xencor's bispecific platform could extend beyond oncology into...

      Nov 12Yahoo FinanceXNCR
      Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657
      Nov 9Yahoo FinanceXNCR
      Xencor (XNCR) Stock Trades At A Premium To Its Sales
      Nov 5Yahoo FinanceXNCR
      Xencor: Q3 Earnings Snapshot
      Nov 4Yahoo FinanceXNCR
      Xencor Reports Third Quarter 2026 Financial Results
      Nov 4Yahoo FinanceXNCR
      Xencor stock hits 52-week high at 33.62 USD
      Nov 4Investing.comXNCR
      Canaccord Genuity Keeps Their Buy Rating on Xencor (XNCR)

      Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.

      Oct 28The Globe and MailXNCR
      Xencor Sees Upside Potential After 'Exciting' Kidney Cancer Trial Data, RBC Capital Markets Says
      Oct 27Yahoo FinanceXNCR
      Truist raises Xencor stock price target on kidney cancer drug data
      Oct 27Investing.comXNCR
      Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma - Slideshow (NASDAQ:XNCR) 2026-10-27

      2026-10-27. The following slide deck was published by Xencor, Inc.

      Oct 27Seeking AlphaXNCR
      RBC Raises Price Target on Xencor to $43 From $20, Keeps Outperform, Speculative Risk
      Oct 27Yahoo FinanceXNCR
      Wells Fargo raises Xencor stock price target on kidney cancer data
      Oct 27Investing.comXNCR
      RBC Capital raises Xencor stock price target on cancer drug data
      Oct 27Investing.comXNCR
      Xencor (XNCR) Is Up 15.8% What's Changed After Kidney Cancer Trial Update
      Oct 26Yahoo FinanceXNCR
      Xencor soars 16% on encouraging early XmAb819 data (XNCR:NASDAQ)
      Oct 26Seeking AlphaXNCR
      Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway
      Oct 26Seeking AlphaXNCR
      Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
      Oct 26Yahoo FinanceXNCR
      Xencor Soars 31% on Kidney Cancer Trial Data Showing “Impressive Antitumor Activity”
      Oct 26Yahoo FinanceXNCR
      Why Is Xencor Stock Trading Higher Today? - Xencor (NASDAQ:XNCR)
      Oct 26BenzingaXNCR
      Xencor shares jump as kidney cancer drug data support Phase 3 plans
      Oct 26Yahoo FinanceXNCR
      Xencor stock surges on positive cancer drug trial data
      Oct 26Investing.comXNCR
      Wedbush Adjusts Price Target on Xencor to $45 From $30, Maintains Outperform Rating
      Oct 26Yahoo FinanceXNCR
      Xencor stock hits 52-week high at 32.29 USD
      Oct 26Investing.comXNCR
      Why is Xencor stock surging today?
      Oct 26Investing.comXNCR
      Biotech Catapults On 'Unprecedented' And 'Profound' Data

      Shares hit a nearly four-year high on positive results in kidney cancer.

      Oct 26Investor's Business DailyXNCR
      12 Health Care Stocks Moving In Monday's Pre-Market Session
      Oct 26BenzingaSPRCXNCR
      Xencor Shares Rise Pre-Bell After Kidney Cancer Trial Shows 45.5% Response Rate
      Oct 26Yahoo FinanceXNCR
      Xencor reports promising kidney cancer drug results, plans late-stage trial (XNCR:NASDAQ)
      Oct 25Seeking AlphaXNCR
      Xencor reports phase 1 data for cancer drug XmAb819
      Oct 25Investing.comXNCR
      Is Xencor (XNCR) A Bargain After Its XmAb819 Phase 1 Update?
      Oct 19Yahoo FinanceXNCR
      Xencor to present phase 1 data for kidney cancer treatment
      Oct 19Investing.comXNCR
      Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
      Oct 19Yahoo FinanceXNCR
      RBC Capital Remains a Buy on Xencor (XNCR)

      Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.

      Oct 17The Globe and MailXNCR
      Xencor Stock: Better Funding For Obexelimab (NASDAQ:XNCR)
      Oct 7Seeking AlphaXNCR
      Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and IQVIA Holdings (IQV)

      Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailXNCRIQV
      Truist raises Xencor stock price target to $29 on drug trial outlook
      Sep 28Investing.comXNCR
      BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating

      Xencor (XNCR) has an average rating of overweight and mean price target of $31.25, according to anal

      Sep 21Yahoo FinanceXNCR
      Xencor (XNCR) Receives a Buy from Barclays

      Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.

      Sep 12The Globe and MailXNCR
      Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift
      Sep 9Investing.comXNCR
      Xencor to Present at the 2026 Cantor Global Healthcare Conference

      PASADENA, Calif., September 02, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.

      Sep 2Yahoo FinanceXNCR
      Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating
      Sep 1Yahoo FinanceXNCR

      This is the newest page. Registered accounts read further back.